Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | purinergic receptor P2Y, G-protein coupled, 11 | Starlite/ChEMBL | References |
Homo sapiens | purinergic receptor P2Y, G-protein coupled, 14 | Starlite/ChEMBL | References |
Homo sapiens | pyrimidinergic receptor P2Y, G-protein coupled, 6 | Starlite/ChEMBL | References |
Homo sapiens | purinergic receptor P2Y, G-protein coupled, 2 | Starlite/ChEMBL | References |
Homo sapiens | PPAN-P2RY11 readthrough | References | |
Homo sapiens | purinergic receptor P2Y, G-protein coupled, 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | purinergic receptor P2Y, G-protein coupled, 1 | 373 aa | 393 aa | 17.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | peter pan protein, putative | 0.0075 | 0.5 | 0.5 |
Schistosoma mansoni | peter pan-related | 0.0075 | 0.5 | 0.5 |
Leishmania major | peter pan protein, putative | 0.0075 | 0.5 | 0.5 |
Schistosoma mansoni | peter pan-related | 0.0075 | 0.5 | 0.5 |
Onchocerca volvulus | Peter pan protein homolog | 0.0075 | 0.5 | 0.5 |
Trichomonas vaginalis | ssf, putative | 0.0075 | 0.5 | 0.5 |
Giardia lamblia | Peter pan protein | 0.0075 | 0.5 | 0.5 |
Echinococcus granulosus | peter pan | 0.0075 | 0.5 | 0.5 |
Echinococcus multilocularis | peter pan | 0.0075 | 0.5 | 0.5 |
Trypanosoma brucei | brix domain containing protein, putative | 0.0075 | 0.5 | 0.5 |
Toxoplasma gondii | brix domain-containing protein | 0.0075 | 0.5 | 0.5 |
Loa Loa (eye worm) | brix domain-containing protein | 0.0075 | 0.5 | 0.5 |
Entamoeba histolytica | brix domain containing protein | 0.0075 | 0.5 | 0.5 |
Plasmodium falciparum | BRIX domain, putative | 0.0075 | 0.5 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0075 | 0.5 | 0.5 |
Trypanosoma cruzi | peter pan protein, putative | 0.0075 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Fu (ADMET) | < 0.2 % | Fraction unbound in human serum | ChEMBL. | 23602442 |
IC50 (binding) | = 29 nM | Antagonist activity at P2Y1 receptor in washed human platelets assessed as 1 uM 2-methylthio-ADP-induced calcium flux by FLIPR assay | ChEMBL. | 24164581 |
IC50 (binding) | = 2.1 uM | Antagonist activity at P2Y1 receptor in platelet-enriched human plasma assessed as 2.5 uM ADP-induced platelet aggregation preincubated for 1 min followed by ADP induction measured at 5 mins by aggregometric analysis | ChEMBL. | 24164581 |
Ki (binding) | = 6 nM | Displacement of [beta-33P]-2MeS-ADP from human P2Y1 receptor transfected in HEK293 cells assessed as residual [beta-33P] bound to plate after 1 hr by scintillation counting analysis | ChEMBL. | 23368907 |
Ki (binding) | = 6 nM | Binding affinity to human P2Y1 receptor | ChEMBL. | 23602442 |
Ki (binding) | = 6 nM | Displacement of [33P]-2MeS-ADP from human P2Y1 receptor expressed in HEK293 cells after 1 hr by scintillation counting analysis | ChEMBL. | 24164581 |
Ki (binding) | = 3500 nM | Inhibition of human P2Y14 receptor | ChEMBL. | 23368907 |
Ki (binding) | > 15000 nM | Inhibition of human P2Y11 receptor | ChEMBL. | 23368907 |
Ki (binding) | > 15000 nM | Inhibition of human P2Y6 receptor | ChEMBL. | 23368907 |
Ki (binding) | > 15000 nM | Inhibition of human P2Y2 receptor | ChEMBL. | 23368907 |
Ki (binding) | > 70000 nM | Displacement of [beta-33P]-2MeS-ADP from human P2Y12 receptor transfected in HEK293 cells assessed as [beta-33P] bound to cells after 1 hr by scintillation counting analysis | ChEMBL. | 23368907 |
permeability (ADMET) | = 21 nm/s | Permeability across human Caco2 cells | ChEMBL. | 23368907 |
PPB (ADMET) | = 99.3 % | Plasma protein binding in human | ChEMBL. | 23668989 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
3 literature references were collected for this gene.